Probi signs distribution agreement with Ta`am Teva Altman in Israel regarding Lp299v™ dietary supplements

Probi signs distribution agreement with Ta`am Teva Altman in Israel
regarding Lp299v™ dietary supplements 

Probi has signed an agreement giving Ta`am Teva Altman rights to launch
Probi's dietary supplement for gut health based on Lp299v™ in Israel.
The launch is planned to take place in the second quarter of 2011. 

“Ta`am Teva Altman is one of the leaders in consumer healthcare in
Israel and the company is also well-known internationally. I am
particularly pleased that we are able to move quickly to launch,” says
Michael Oredsson, CEO of Probi.

The Israeli VMS market is estimated at 200 million US dollars and is
expected to have an annual growth of approximately 10 percent.

Dietary supplements based on Probi's probiotics are sold or are in the
process of being launched in more than 40 countries worldwide.

The information is such that Probi AB must disclose in accordance with
the Swedish Securities Market Act and/or the Financial Instruments
Trading Act.

FOR FURTHER INFORMATION, CONTACT:

Michael Oredsson, CEO, Probi, phone. +46 46 286 89 23 or mobile. +46 707
18 89 30

e-mail: michael.oredsson@probi.se

Niklas Bjärum, VP Marketing & Sales, Probi, phone. +46 46 286 89 67 or
mobile. +46 705 38 88 64
e-mail: niklas.bjarum@probi.se